NORTH AMERICA DIPEPTIDE PEPTIDASE 4 (DPP-4) INHIBITORS Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

NORTH AMERICA DIPEPTIDE PEPTIDASE 4 (DPP-4) INHIBITORS Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Key Highlights

• North American Dipeptide Peptidase 4 (DPP-4) inhibitors Market is 13.9% of the North America diabetes drug market and is expected to witness the steady CAGR of 1.3%.
• The North American DPP-4 drugs segment of the market studied accounted for the highest revenue in 2017.
• It is estimated that within the Region with the age-adjusted prevalence of diabetes for the USA estimated at 9.2%, 7.9% for Canada, 12.6% for Mexico, and 9.6% for the Caribbean islands.
• The economic impact was also huge, the healthcare spending due to diabetes estimated to be 263.2 billion USD in 2013, the highest of all Regions

Key Market TrendsJanuvia holds the highest market share in DPP-4 market

• Januvia holds the significant share in a DPP-4 market in 2018 which is likely to get replaced by Tradjenta in the forecast period.
• DPP-4 inhibitors are second to third line treatment of diabetes type-2, it is an incretin-based drug which controls hyperglycemia by hindering the action of the DPP-4 enzyme, which leads to the increase in GLP-1 concentration in the body.
• Some animal studies suggested that there could be a possibility of this inhibition cause IBD, but the direct effect is still unclear.

USA holds the highest market share in North America

• The North America DPP-4 Market is 53.5% of the total DPP-4 market, USA holds a significant share in the North America DPP-4 market. The USA DPP-4market is expected to increase because of increasing diabetes and obesity population in the country.

Competitive Landscape

• The DPP-4 inhibitor drugs market is consolidated with few major manufacturers boasting a global market presence, while few generic drugs are with the remaining manufacturers confining to the other local or region-specific manufacturers.
• Major market players in the DPP-4 inhibitor drugs are Merck, AstraZeneca, Eli Lilly.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.